A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial - The Lancet Regional Health – Americas
For Authors: Submit your work
Robustness of evidence reported in preprints during peer review - The Lancet Global Health
Reporting and data sharing level for COVID-19 vaccine trials: A cross-sectional study - eBioMedicine
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial - The Lancet
The Lancet Commission on lessons for the future from the COVID-19 pandemic - The Lancet
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial - The Lancet
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study - The Lancet Infectious Diseases
Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review - eClinicalMedicine
Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study - The Lancet Infectious Diseases
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression - The Lancet
The Lancet Infectious Diseases, January 2024, Volume 24, Issue 1, Pages 1-106, e1-e69
The Lancet Microbe Home Page
How swamped preprint servers are blocking bad coronavirus research
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression - The Lancet Infectious Diseases
Preprints with The Lancet: joining online research discussion platforms - The Lancet
Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis - The Lancet
For Authors: Submit your work
Lancet COVID-19 Commission Statement on the occasion of the 75th session of the UN General Assembly - The Lancet
For Authors: Submit your work
A new paradigm is needed to explain long COVID - The Lancet Respiratory Medicine
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial - The Lancet
Preprints are the future but peer review is still king' - Research Professional News
Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil - The Lancet
First Look - SSRN | Elsevier
The Lancet Regional Health – Americas
Prepublication and clinical practice: challenges ahead
The Lancet Oncology
